Xponance Inc. Invests $216,000 in Guardant Health, Inc. (NASDAQ:GH)

Xponance Inc. acquired a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 7,479 shares of the company’s stock, valued at approximately $216,000.

A number of other large investors also recently bought and sold shares of the business. Canton Hathaway LLC bought a new stake in shares of Guardant Health during the second quarter worth $59,000. Byrne Asset Management LLC purchased a new stake in Guardant Health in the 2nd quarter valued at about $77,000. Manchester Capital Management LLC bought a new position in Guardant Health in the 1st quarter worth about $57,000. EntryPoint Capital LLC bought a new position in Guardant Health in the 1st quarter worth about $75,000. Finally, Fullcircle Wealth LLC purchased a new position in shares of Guardant Health during the second quarter worth approximately $211,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Guardant Health Stock Performance

Shares of GH stock opened at $22.36 on Thursday. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $37.04. The business’s fifty day simple moving average is $27.53 and its 200-day simple moving average is $25.29. The company has a current ratio of 6.40, a quick ratio of 6.07 and a debt-to-equity ratio of 16.70. The company has a market cap of $2.74 billion, a PE ratio of -5.70 and a beta of 1.11.

Guardant Health (NASDAQ:GH) last announced its earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.10). The business had revenue of $177.24 million for the quarter, compared to analyst estimates of $162.59 million. Guardant Health had a negative net margin of 76.23% and a negative return on equity of 418.21%. The company’s quarterly revenue was up 29.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.67) earnings per share. Analysts expect that Guardant Health, Inc. will post -3.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. TD Cowen increased their price objective on Guardant Health from $41.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. increased their price target on Guardant Health from $45.00 to $48.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. Craig Hallum lifted their price objective on Guardant Health from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 8th. BTIG Research upped their price objective on shares of Guardant Health from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. Finally, The Goldman Sachs Group boosted their price target on shares of Guardant Health from $28.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 17th. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and a consensus target price of $39.67.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.